

### Help us fund a Postdoctoral Fellowship at the M.D. Anderson Cancer Center

Drs. Wadih Arap and Renata Pasqualini are leading an exciting new chapter in prostate cancer research based on their discovery that the

human vasculature system contains unique molecular addresses. The blood vessels in organs and tissues, including prostate cancer tumors, have specific "ZIP codes" that can be targeted and disrupted. Through development of an "imaging transcriptome", they will be able to visualize, in real time and in a non-invasive

manner, a panel of genes that are being turned on or off within prostate cancers, as a result of therapeutic intervention.

Will you help us attain the goal of \$75,000 to fund a one-year post-doctoral fellow at M.D. Anderson? If everyone who receives this report donates \$75, we will

have enough to fund the fellowship. You can help by making a donation of any amount now using the envelope enclosed.

The fellowship can be named after a family or person should a generous donor wish to fully fund the fellowship. Thank You!

## Please join us in 2010.

**April 16** Hands & Hearts North Carolina at Fearington Inn, Pittsboro, NC with Chef Colin Bedford

**April 28** Hands & Hearts Silicon Valley at Stonebrook Court, Los Altos Hills, CA with Chef Ken Frank of La toque

**May 12** Hands & Hearts New York City at Le Bernardin in Manhattan with Chef Eric Ripert

**August 7** Stars 2010 at Côte Deux Mille at the Peter Michael Estate in Sonoma, CA with Chef Michel Richard of Citronelle

Please contact us for more information.

Walter Menzel, Executive Director [walter@petermichaelfoundation.org](mailto:walter@petermichaelfoundation.org)  
Jenny Koehler, Event Manager [jenny@petermichaelfoundation.org](mailto:jenny@petermichaelfoundation.org)  
Office: 415-339-0400 [www.petermichaelfoundation.org](http://www.petermichaelfoundation.org)

The Sir Peter and Lady Michael Foundation is a 501(c)(3) corporation. Federal ID #94-3238961.

*Dear Friends,*

*This is as much a personal letter as it is a year-end report.*

As I compose it, I clearly see the faces of the wonderful people I have gotten to know as a result of the Foundation's work. Were it possible, I would address this to each of you individually.

2009 was a challenging year. The Foundation was able to continue support of the post doctoral fellows for which it had made prior commitments but we were not able to grow beyond that. We are cautiously optimistic about 2010 and appeal to you for your help.

## YEAR IN REVIEW 2009

### OUR STRATEGY

The Peter Michael Foundation operates differently than most medical charities. Our Best-of-Class Prostate Cancer Research Investment Strategy is a disciplined, focused approach for identifying high potential prostate cancer research opportunities. Similar in some ways to a venture capital firm, we:

- A** source innovative research opportunities from around the US
- B** vet them among oncologists, scientists, and life sciences executives on our Board of Advisors
- C** fund those that meet our strategic guidelines and requirements
- D** track the results through regular contact, written reports and a bi-annual Prostate Cancer Colloquium

Four-year postdoctoral prostate cancer research fellowships have been underwritten with leading scientists at the following three world-class medical institutions. Please read their summary reports later in this publication.

### MEMORIAL SLOAN-KETTERING CANCER CENTER:

Hedvig Hricak, MD, PhD, Chair of Radiology

### STANFORD UNIVERSITY CANCER CENTER:

Sanjiv Sam Gambhir, MD, PhD, Head of Nuclear Medicine, Director of Molecular Imaging Program, Professor of Radiology and Bioengineering

### UNIVERSITY OF CALIFORNIA INSTITUTE FOR QUANTITATIVE BIOMEDICAL RESEARCH:

Daniel B. Vigneron, PhD, Professor of Radiology

### OUR NICHE

Broadly speaking, there are two funding sources for medical research—the government or private financing.

At one end, the National Institute of Health (NIH) and the Department of Defense both fund prostate cancer research. However, medical scientists and researchers have stated that the process doesn't lend itself to funding truly innovative work. They have said that it is the safer, near-in studies that get funded in part because of the government's own directives and the arduous, grant application process. On the other end of the spectrum is private financing through a variety of means. However, most private investors are looking for a drug, device, or treatment that has large, immediate commercial potential.

The Peter Michael Foundation identifies prostate cancer research opportunities in between those two poles. We seek out significant, innovative research that is overlooked or unfunded. These tend to be high potential projects but may take a longer to get from bench to bedside. An example is Dr. Sam Gambhir's cutting edge PhotoAcoustic Imaging Research at Stanford Cancer Center. The Foundation has arranged

for a four year postdoctoral fellowship named after and fully funded by a donor family in Los Angeles who have been strategically involved and financially supportive of the Peter Michael Foundation since its inception.

The goal of Dr. Gambhir's project is to create a "theranostic" system, i.e. diagnostics plus therapy, for treating prostate cancer individually and on a molecular level. It begins with the creation of an imaging agent, what Dr. Gambhir calls a nuclear spy. This is a nanoengineered protein specifically designed to seek out, identify, and ultimately destroy prostate cancer anywhere in the body at the cellular level. The imaging agent is injected into the body, dispersed by the bloodstream, and quickly attaches to prostate cancer cells wherever they are. Then a laser light is passed over the body causing those proteins that have attached to cancer cells to emit an audio signal out of the body that is imaged on an external imaging device. Hence the name PhotoAcoustic. The next step in the process would be to send an audio signal back into the body that triggers a payload on the nanoengineered protein to destroy the cancer cell. When this achieves clinical trials, it will be an exceptional example of a personalized prostate cancer treatment that will have applications to other soft tissue cancers.

### CHALLENGING FUNDRAISING ENVIRONMENT

Peter Michael Foundation funding originates almost entirely from individual donations and attendance at Hands & Hearts culinary events around the US. As everyone knows, 2009 was a difficult year. The Peter Michael Foundation was no exception with fundraising revenue significantly below the prior year. While we were able to continue underwriting the three fellowships mentioned earlier, we were not able to expand support of other significant opportunities with individuals and institutions we have vetted.

### HOW TO HELP

You can help now by making a donation of any amount using the envelope enclosed. We can support a postdoctoral fellowship at M. D. Anderson for one year if we can raise \$75,000. To make this more tangible, if everyone who receives this report donates \$75, we will have enough to fund the fellowship. The fellowship can be named after a family or person should a generous donor wish to fully fund the fellowship.

There is a significant research opportunity under the direction of Drs. Wadih Arap and Renata Pasqualini, preeminent prostate cancer scientists at M. D. Anderson Cancer Center in Houston. While investigating cancer metastasis, this team discovered that the human vascular system has what have been termed "zip codes" that steer different cancers to certain target sites, but not to others. We would like to build on their research by underwriting a postdoctoral fellowship under their direction but do not have sufficient funds to do so.

### APPRECIATION

I am deeply grateful for the support, friendship, and guidance of our donors, the Michael family, our Boards of Directors and Advisors, and the fantastic staffs of the Peter Michael Winery and the Peter Michael Foundation. And I am honored and inspired by the physicians and scientists we work with.

Thank you all.

Walter B. Menzel  
Executive Director

## Stanford University Cancer Center 2009 Progress Report

### BACKGROUND

Standard screening methods for prostate cancer - such as blood screening for prostate specific antigen (PSA), digital rectal examination (DRE), and transrectal ultrasound (TRUS) guided prostate biopsy - have limited ability (sensitivity and specificity) in the early diagnosis of prostate cancer. Physicians employ a combination of these methods to improve diagnosis. Unfortunately, even a combination of all the above three methods of evaluation lack overall diagnostic accuracy. Other emerging imaging modalities for prostate diagnosis, such as MRI (magnetic resonance imaging), CT (computed tomography), PET (positron emission tomography) suffer from problems that include employing ionizing radiation (CT and PET), limited soft tissue contrast (CT), limited sensitivity (CT and MRI), limited spatial resolution (PET) and high cost (MRI, PET, and CT). However, TRUS employs non-ionizing radiation and is relatively cheap and continues (despite some pitfalls) to be the most successful imaging technique in the screening stage.


To improve the diagnostic accuracy of TRUS, we propose transrectal photoacoustic (TRPA) imaging of the prostate with sub-millimeter spatial resolution and high soft tissue contrast based on both endogenous (blood vasculature) and exogenous molecular imaging agents. Since TRPA and TRUS share a common platform-ultrasound detection, TRPA can be easily built on the strengths of TRUS. This facilitates multimodality (ultrasound and photoacoustic) imaging of prostate using one common device, where structural information of prostate can be obtained using TRUS and functional and targeted imaging can be obtained using TRPA. As physicians are familiar with TRUS, this combined device will likely enable easy physician acceptance and clinical translation. The literature on photoacoustic imaging suggests that TRPA would have enough sensitivity to detect early cancer, at extremely small concentrations and yet highly targeted (specificity due to photoacoustic molecular imaging agents).

### PRELIMINARY RESULTS

The key challenge of photoacoustic (PA) imaging has been limited depth penetration compared to conventional ultrasound imaging. Our study on transrectal sonograms of prostate show that average distance of the TRUS probe to the far end of prostate lobe is approximately 5 cm. Our primary aim is to develop a TRPA probe and evaluate the depth penetration in a tissue mimicking phantom. We used state of art 16x16 element array CMUTs with integrated electronics for our photoacoustic experiments. CMUT technology offers advantages such as wide bandwidth, sensitivity, very high level of integration and batch fabrication (low cost) and thus is expected to replace conventional piezoelectric transducers. Figures (a) and (c) show the schematic experimental setup. Tunable (675 nm to 800 nm) laser light illuminates the phantom along the X-axis. A CMUT is placed below the phantom along the Z-axis. The tissue mimicking phantom sample (XYZ dimensions of 7 cm x 5 cm x 7 cm) with strong optical scattering ( $\mu_s = 10 \text{ cm}^{-1}$ ) contains horse hair objects at 3.5 cm, 4 cm, 4.5 cm, and 5 cm depths along both the X and Z axes. These objects absorb diffused laser light and generate PA signal. Each element (total 256 elements) of CMUT is then scanned electronically to detect the PA signal. This generates local volumetric data within the field of view of CMUT. Phantom sample (or CMUT) is then scanned to generate desired volumetric data. Figure (b) shows reconstructed volumetric data of all 4 embedded objects at different depths.


Sanjiv Sam Gambhir, MD, PhD  
(right) Head, Division of Nuclear Medicine

Raj Kothapalli, MD, PhD (left)  
Pelican Postdoctoral Fellow



### FUTURE DIRECTIONS

- 1) As shown in figure (d), current CMUT + associated electronics is 3.3 cm wide. But the rectal opening is only 3.2 cm wide. We will receive a 1 cm x 1 cm wide CMUT soon.
- 2) Once received, we integrate optical fibers (for light delivery) with CMUTs and package it to make TRPA probe which will look like a clinically used TRUS probe.
- 3) Then the TRPA probe will be tested using PA prostate phantoms (not shown here due to limited space) that we built in our lab. These prostate phantoms simulate both optical and acoustical properties of rectal wall, prostate (both benign and malignant), urethra, and seminal vesicles.
- 4) Light delivery through urethra will be considered in case of limited penetration depth of TRPA probe.
- 5) We are simultaneously developing Monte Carlo simulations to simulate TRPA imaging of prostate.
- 6) Using the above mentioned simulations and experiments we will optimize performance of the probe.
- 7) Then we plan to test the TRPA probe in a canine prostate model, and later employ functional and molecular imaging strategies that we are developing, with this TRPA probe.



### SUPPLEMENTARY POINT

Dr. Raj Kothapalli, Pelican Fellow at Stanford, occasionally visits the VA hospital affiliated to Stanford, to watch and learn (under guidance of Dr. Joe Liao) all clinical procedures related to prostate screening (such as TRUS biopsy of prostate) and surgery (e.g., prostatectomy).

## University of California Institute for Quantitative Biomedical Research 2009 Progress Report



Daniel B. Vigneron, PhD  
Professor, Department of Radiology  
Dr. Peder Larson, PhD  
Pelican Postdoctoral Fellow

Improved imaging is required for more accurate treatment selection, guidance and evaluating current and emerging therapies. Another research focus of the UCSF prostate cancer imaging research is to better monitor patients who have deferred treatment and are under "active surveillance." In these patients, the goal is to better characterize and changes in the cancers that would indicate the need for treatment. The need for improved prostate cancer imaging was clearly stated in the consensus of participants of the Colloquium on Prostate Cancer, sponsored by the Pelican Cancer Foundation in 2008 in the United Kingdom. This continues to be an under-funded area of research, but a very necessary one that offers great potential benefit to prostate cancer patients.

With the generous support of the Peter Michael Foundation, prostate cancer imaging research at the University of California, San Francisco advanced greatly in 2009. Highlights include being awarded \$1.2M in stimulus funds from the National Institutes of Health (NIH), working with medical device companies to make our multi-parametric prostate MRI techniques commercially supported with widespread availability, and the development of new metabolic imaging methods to assess prostate cancer aggressiveness (a critical clinical management problem).

Under the direction of Professor Daniel Vigneron, Ph.D., the research team including the Pelican Fellow, Dr. Peder Larson Ph.D., works on developing and testing improved methods for anatomic and metabolic Magnetic Resonance imaging (MRI) of prostate cancer.

In 2009, the funding from the Peter Michael Foundation has supported the effort of Dr. Peder Larson Ph.D. as a Pelican Fellow researching new prostate cancer imaging methods. He is an outstanding young imaging scientist who has a very strong background in basic science through his graduate studies in electrical engineering at Stanford University. At UCSF he has gained in-depth knowledge of prostate cancer biology, physiology and clinical management issues. He has applied his strong knowledge of basic physics and engineering to develop new magnetic resonance imaging (MRI) techniques for improved prostate cancer imaging. His efforts have been divided into two areas. One is short term improvements of MRI techniques for current patients studies to provide improved speed, scope, and information content. His improved methods are now used in hundreds of prostate cancer patient studies at UCSF and through our collaboration with GE Healthcare these methods are now being applied in initial evaluations at other major prostate cancer imaging sites including Memorial Sloan-Kettering in

New York. GE plans to include this as a clinical product in future commercial releases starting later this year. Dr. Larson's other research focus is on the development of new metabolic imaging methods which will take a longer time to be clinically available. This project is to develop a new method called hyperpolarized carbon-13 MRI.

This exciting new metabolic imaging technique with General Electric Healthcare will take somewhat longer to develop but provides over 50,000-fold improvement for imaging cellular metabolism. This new method was developed by GE scientists and through a collaboration with UCSF, it is being further refined with the goal of initiating the first prostate cancer patient trial later this year. Initial studies in prostate cancer cell cultures and model systems have shown the ability to detect the abnormal metabolism of prostate cancer and differences with progression and response to therapy. Dr. Larson is specifically working on developing and optimizing new acquisition methods for improved pre-clinical studies and for the first human studies. This extraordinary new technique has the potential to become an important new radiological tool for metabolic imaging by directly observing specific metabolic pathways in prostate cancer that can characterize prostate cancer aggressiveness and response to treatment.

## 2009 Foundation Events

### HANDS & HEARTS NEW YORK



Captions can go here  
left: Chef Thomas Keller; Barbara White, Gardner Robinson and Donnie Hays; Kip Eaton and Daneen Griffin; Erika von Petrin, Robin Bellas and Tamsinn Cowart; Fred and Margaret Carl; Kevin and Gabriela York and Dr. Tom Carlson; Gordon and Sharon Bower; Sir Peter Michael and Dick Kramlich

### HANDS & HEARTS ST. LOUIS

## 2009 SUPPORTERS

*Please forgive any errors or omissions, but also bring them to our attention.*

Dr. Wadiah Arap  
Mr. & Mrs. Bart Araujo  
Mr. Morris J. Baller  
Ms. Leslie Barbi  
Mr. Joseph Barone  
Mr. & Mrs. Richard Barry III  
Mr. Aaron Bell  
Mr. & Mrs. Robert C. Bellas, Jr.  
Ms. Donna Bertani  
Dr. James Bianco  
Mr. Christopher Bloomstran  
Mr. & Mrs. John Bolton  
Bonhams & Butterfields  
Mr. & Mrs. Dennis Boone  
Ms. Christine Brigagliano  
Mr. & Mrs. Howard Brous  
Mr. & Mrs. Charles Brown  
Mr. & Mrs. Dennis C. Brydon  
Mr. Troy Campione  
Mr. & Mrs. Gene Carlisle  
Dr. Thomas A. Carlson  
Ms. Brenda Chaparro  
Ms. Rebecca Chekouras  
Ms. Ann Colgin  
Ms. Sarah Crane  
Mr. Fred Craves  
Mr. Andrew Cross  
Ms. Andrea Crow  
Dr. Carey Cullinane  
Ms. Alison DeBord  
Mr. William Decherd  
Mr. Jack Del Rio, Jr.  
Mr. & Mrs. Dean Dennis  
Ms. Patricia Diviero  
Mr. & Mrs. James East  
Mr. Winston Eaton  
Mr. & Mrs. Chris Ehrlich  
Mr. George S. Elliott  
Mr. Brian Eveslage  
Mr. & Mrs. John F. Ferring IV  
The French Laundry  
Mr. & Mrs. Eliot Fried

Mrs. Judy Gaulke  
Dr. & Mrs. Carl Goldfischer  
Mr. & Mrs. George Grasso  
Mr. Richard Green  
Mr. & Mrs. Howard Haber  
Ms. Mary Hall-Ries  
Mr. Pasi M. Hamalainen  
Mr. Richard Hermanson  
Mr. Paul Hobbs  
Mrs. Susan Cook Hoganson  
Mr. & Mrs. Vernon P. Horn  
Mr. Mark Howald  
Dr. Hedvig Hricak  
Mr. Dennis Ivan  
Ivey-Selkirk Auctioneers  
Dr. Hank Jones  
Ms. Marge Josephson  
Chef Thomas Keller  
Mr. & Mrs. Charles R. Kirk  
Mr. Mark Knudson  
Chef Chris Kollar  
Mr. & Mrs. Marc Lazar  
Mr. Chad LaBenz  
Mr. Jim Lokey  
Mr. Andrew B. Lustigman  
Mr. Mark MacLennan  
Mr. Mark Maier  
Mr. Willi Maier  
Mr. & Mrs. Hunter Martin  
Dr. Sue Masten  
Mr. Douglass McKellar, Jr.  
Mr. Bill McMahon  
Mr. & Mrs. Patrick Meade  
Mr. & Mrs. Mark Merlotti  
Mr. & Mrs. Glenn Meyers  
Mr. Michael Meyers  
Dr. Shawn C. Merys  
Mr. & Mrs. Paul Michael  
Sir Peter and Lady Michael  
Mr. Mark E. Miller  
Mr. & Mrs. Luc Morlet  
Dr. Scott Multack  
Mr. Don Musick III  
Mr. Erik A. Noteboom  
Ms. Shannon Nyimicz  
Mr. & Mrs. Ed Ojdana

O'Melveny & Myers, LLP  
Mr. & Mrs. Timothy Ord  
Ms. Jennifer Padovani  
Ms. Lynne Pantalena  
Dr. Renata Pasqualini  
Per Se  
Peter Michael Winery  
Mr. & Mrs. Hank Plain  
Ms. Belva Rasmussen  
Ms. Lauren Ridenhour  
Mr. Eric Roberts  
Mr. & Mrs. Scott Rodde  
Ms. Veronica Rodriguez  
Mr. David Schachter  
Mr. & Mrs. Robert K. Schacter  
Schaffer&Combs  
Mr. Martin Sigillito  
Mr. Eric Sigurdson  
Mr. & Mrs. David Sindelar  
Mr. Robert Sleight  
Mr. Frances Smith  
Mr. Roger V. Smith  
Sotheby's  
Mr. Sy Sternberg  
St. Louis Racquet Club  
Mr. Paul Tanico  
Ms. Susan Thomas  
Ms. Nancy Tkalcevic  
Mr. & Mrs. Markus Trice  
Mr. Mat Turner  
Mr. & Mrs. Jon Underwood  
Ms. Tina Vaughn  
Dr. Daniel B. Vigneron  
Viking Range Corporation  
The Vineyard at Stockcross  
Thomas E. Warner Wine Cellar  
Company  
Ms. Barbara White  
Mr. Lonny White  
Mrs. Mary Z. Williams  
Mr. Douglas Wolf  
Mr. & Mrs. Kevin York

## Memorial Sloan-Kettering Cancer Center 2009 Progress Report

Dr. Hedvig Hricak, MD, PhD  
*Chairman, Department  
of Radiology*



Dr. Jan Grimm, MD, PhD  
*Pelican Fellow*



**Both clinical and basic research** in advancing the imaging methods of prostate cancer continue to advance in a multidisciplinary approach at Memorial Sloan-Kettering Cancer Center (MSKCC). The group involved in prostate imaging is large and includes, physicists, chemists, pathologists, biologists, radiologists and nuclear medicine physicians, urologists, radiation oncologists and medical oncologists. Dr. Jan Grim was a Pelican

funded fellow and is a member of the group. Last year, Dr. Jan Grimm finished his additional medical training in Nuclear Medicine and fellowship in Body Imaging at MSKCC. Furthermore, he obtained board certification in Nuclear Medicine and joined the faculty of MSKCC. He has a dual appointment in the Radiology Department and an appointment in Molecular Pharmacology and Chemistry at Sloan-Kettering Institute (SKI). Through his appointment at the SKI, Dr Grimm is heading his own laboratory focusing on molecular imaging in oncology. In this laboratory, he is continuing research he began as a Pelican Fellow, developing molecular imaging approaches for cancer, focusing on innovative imaging methods for early detection and better characterization of prostate cancer. As the primary target of his molecular imaging studies he has chosen prostate-specific membrane antigen (PSMA), an antigen highly expressed in prostate cancer cells and neovasculature. PSMA was originally cloned at MSKCC, and there is a long history of research on this transmembrane protein. Its expression correlates with the grade and prognosis of prostate cancer. It also has an enzymatic function that can be exploited for imaging purposes.

### Three ongoing studies in Dr. Grimm's lab are related to prostate cancer:

1) A novel magneto-fluorescent nanoparticle, developed by Dr. Grimm, binds to PSMA and can be detected with both MRI and optical imaging. The lab has since shown the specificity of the agent for PSMA and is currently exploring its utilization as a tool for monitoring the effects of prostate cancer therapy.

2) In collaboration with the organic chemistry core facility at MSKCC, Dr. Grimm also developed a unique agent that senses the enzymatic activity of PSMA. This agent is being studied intensively and used to image prostate cancer in mouse models. The lab is in this case also exploring the expression of PSMA on tumor vessels, which might open a wide field of applications for this agent, leading to other assays on the basis of this agent, which may have the potential for clinical applications.

3) Finally, a novel approach is being pursued to monitor therapies for prostate cancer with PET imaging. Here we are using a clinically approved agent (but for another indication) to detect cells that are killed by either radiation or chemotherapy. This approach allows detection of apoptotic (i.e., dying) prostate cancer cells following therapy such as radiation. Because the agents employed are already in clinical use, the approach could be applied directly in the clinic. An expansion of this project in the near future is planned after publication of these first data, to bring the approach into the clinical arena. All three of Dr. Grimm's prostate cancer imaging projects are in advanced stages and promise to result in translation into clinic within the next few years.